Clinical trial · Observational
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)
NCT06585501CI-TRIAL-00093955REHEARSALcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for HER2-positive Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC) patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastroesophageal Junction Cancer | Gastric Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No drug | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- GC/GEJC
- description
- Patients diagnosed with locally advanced unresectable or metastatic HER2-positive GC/GEJC
- interventionNames
- Other: No drug
Primary outcomes (1)
- measure
- Percentage of patients receiving first-line, second-line, and third-line anti-tumor regimens
- timeFrame
- 72 months
Secondary outcomes (6)
- measure
- Percentage of HER2 sample type and testing method among patients with a first diagnosis of locally advanced or metastatic HER2-positive GC/GEJC
- timeFrame
- 72 months
- measure
- Percentage of re-biopsies and re-biopsies with HER2-positive results among patients with a first diagnosis of locally advanced or metastatic HER2-positive GC/GEJC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria * Patients with pathologically diagnosed locally advanced unresectable or metastatic GC/GEJC (limited to those diagnosed since October 1, 2017) and initiating first-line treatment between January 1, 2018, and March 31, 2023 * Patients aged ≥ 18 years at the time of diagnosis with locally advanced unresectable or metastatic GC/GEJC; HER2-positive status2, determined by either tissue samples from the first biopsy or liquid biopsy samples (if a patient has both tissue and liquid biopsy samples, tissue samples will be the standard). Exclusion criteria * Patients with other primary malignant tumors * Patients enrolled in clinical trials and receiving active anti-cancer therapy after July.1, 2017 (excluding retrospective studies). * Patients with critical missing data in medical records or otherwise deemed for inclusion by the investigator
References
Publications (1)
- DERIVEDWang Y, Liu B, Zhang J, Zhang Y, Yuan X, Chen K, Xie X, Qu X, Yang L, Zhang L, Zhang X. Real-World Treatment Patterns, HER2 Testing Practices, and Clinical Outcomes in HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Adv Ther. 2026 Aug;43(8):3633-3648. doi: 10.1007/s12325-026-03613-4. Epub 2026 May 30. PMID 42217113